Green Cross Banking On Bioreactors To Develop Biosimilars, Biobetters Faster
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Following a deal late last year to jointly develop biopharmaceutical products through disposable bioreactors, South Korea's vaccine giant Green Cross Corp. is expanding its collaboration to sell PBS Biotech, Inc.'s bioreactors to Korean companies
You may also be interested in...
Korea's Green Cross Files For Biobetter Of Shire's Hunter Syndrome Therapy Elaprase; Seeks Global Partners
SEOUL - South Korea's leading vaccine manufacturer Green Cross Corp. took a step forward in the biosimilars sector by submitting a marketing application to Korea FDA for a biobetter of Shire PLC's Elaprase (idursulfase) for Hunter syndrome. And now the company is looking for foreign partners
Korea's Green Cross Files For Biobetter Of Shire's Hunter Syndrome Therapy Elaprase; Seeks Global Partners
SEOUL - South Korea's leading vaccine manufacturer Green Cross Corp. took a step forward in the biosimilars sector by submitting a marketing application to Korea FDA for a biobetter of Shire PLC's Elaprase (idursulfase) for Hunter syndrome. And now the company is looking for foreign partners
Korea's Green Cross Strengthens Vaccine Supply Chain For Growing Export Demand
SEOUL - South Korea's leading vaccine producer Green Cross has opened and begun operation of a vaccine egg farm to build up a stable channel for the supply of flu vaccine eggs to the pharma's vaccine plant in Hwasoon, Southwest of Seoul. The company is preparing for increased domestic competition, but it also benefiting from a pickup in foreign demand